Equity · Healthcare
AKTX
NASDAQAkari Therapeutics (AKTX)
The line runs $8.44 on 28 July through $8.98 on 22 October, on a scale from $6 to $12. Days the market did not trade hold the previous close, flat.
as of Oct 22, 2026
Akari Therapeutics (AKTX) insider trades
In the 90 days to 26 Oct 2026, no Akari Therapeutics insider bought or sold shares on the open market; all 15 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).
Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.
Showing the 12 most recent of 15 compensation filings in this window. The figures above count all of them.
Akari Therapeutics (AKTX) reported financials
SEC EDGARAkari Therapeutics reported net income of −$17.3M for the fiscal year ended 31 Dec 2025.
Akari Therapeutics (AKTX) earnings
Akari Therapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of $0.00; no next date is announced in SEC filings yet.
no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
Akari Therapeutics (AKTX) institutional holders (13F)
SEC EDGAR0 of the 45 institutional funds we track reported a Akari Therapeutics position for the quarter ended 30 Sep 2025; the latest of those filings landed 13 Nov 2025.
Akari Therapeutics (AKTX) fails-to-deliver
SECOn 29 Sep 2026, 930 shares of Akari Therapeutics failed to deliver (about $9K) — the latest of 3 consecutive trading days with recorded fails.
Akari Therapeutics (AKTX): frequently asked questions
Have Akari Therapeutics insiders bought or sold shares recently?
In the 90 days to 26 Oct 2026, no Akari Therapeutics insider bought or sold shares on the open market; all 15 Form 4 filings in that window were grants, exercises, tax withholding or transfers (SEC Form 4).
How many institutions hold Akari Therapeutics?
0 of the 45 institutional funds we track reported a Akari Therapeutics position for the quarter ended 30 Sep 2025, per SEC Form 13F filings.
Has Akari Therapeutics had fails-to-deliver recently?
Yes. The most recent SEC fails-to-deliver record for Akari Therapeutics is dated 29 Sep 2026, when 930 shares failed to deliver.
When did Akari Therapeutics last report earnings?
Akari Therapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of $0.00; no next date is announced in SEC filings yet.
What exchange is Akari Therapeutics listed on?
Akari Therapeutics trades on NASDAQ under the ticker AKTX.
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
Sources
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
- SEC EDGARSEC EDGAR 13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARValuation computed from SEC EDGAR filings